{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T15:07:26Z","timestamp":1775228846292,"version":"3.50.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s12026-022-09316-6","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T14:10:38Z","timestamp":1663078238000},"page":"752-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Guillain-Barr\u00e9 syndrome in association with COVID-19 vaccination: a systematic review"],"prefix":"10.1007","volume":"70","author":[{"given":"Meysam","family":"Abolmaali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Rezania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arman Karimi","family":"Behnagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Negin Mahmoudi","family":"Hamidabad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Gorji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-8471","authenticated-orcid":false,"given":"Zahra","family":"Mirzaasgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"key":"9316_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-240178","volume":"14","author":"MM Raahimi","year":"2021","unstructured":"Raahimi MM, Kane A, Moore CE, Alareed AW. Late onset of Guillain-Barr\u00e9 syndrome following SARS-CoV-2 infection: part of \u2018long COVID-19 syndrome\u2019? BMJ Case Reports CP. 2021;14: e240178.","journal-title":"BMJ Case Reports CP"},{"key":"9316_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","volume":"388","author":"HJ Willison","year":"2016","unstructured":"Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barr\u00e9 syndrome. Lancet. 2016;388:717\u201327.","journal-title":"Lancet"},{"issue":"10280","key":"9316_CR3","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barr\u00e9 syndrome. The Lancet. 2021;397(10280):1214\u201328.","journal-title":"The Lancet"},{"key":"9316_CR4","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1056\/NEJMc2009191","volume":"382","author":"G Toscano","year":"2020","unstructured":"Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2. N Engl J Med. 2020;382:2574\u20136.","journal-title":"N Engl J Med"},{"key":"9316_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jocn.2020.11.013","volume":"83","author":"M Abolmaali","year":"2021","unstructured":"Abolmaali M, Heidari M, Zeinali M, Moghaddam P, Ghamsari MR, Makiani MJ, et al. Guillain-Barr\u00e9 syndrome as a parainfectious manifestation of SARS-CoV-2 infection: a case series. J Clin Neurosci. 2021;83:119\u201322.","journal-title":"J Clin Neurosci"},{"issue":"10","key":"9316_CR6","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1111\/ene.14860","volume":"28","author":"L Palaiodimou","year":"2021","unstructured":"Palaiodimou L, Stefanou MI, Katsanos AH, Fragkou PC, Papadopoulou M, Moschovos C, et al. Prevalence, clinical characteristics and outcomes of Guillain\u2212Barr\u00e9 syndrome spectrum associated with COVID-19: A systematic review and meta-analysis. Eur J Neurol. 2021;28(10):3517\u201329.","journal-title":"Eur J Neurol"},{"key":"9316_CR7","first-page":"150","volume":"8","author":"M Petr\u00e1\u0161","year":"2020","unstructured":"Petr\u00e1\u0161 M, Kr\u00e1lov\u00e1 Lesn\u00e1 I, D\u00e1\u0148ov\u00e1 J, \u010celko AM. Is an increased risk of developing Guillain-Barr\u00e9 syndrome associated with seasonal influenza vaccination? A systematic review and meta-analysis Vaccines. 2020;8:150.","journal-title":"A systematic review and meta-analysis Vaccines"},{"key":"9316_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007622","volume":"13","author":"A Capasso","year":"2019","unstructured":"Capasso A, Ompad DC, Vieira DL, Wilder-Smith A, Tozan Y. Incidence of Guillain-Barr\u00e9 syndrome (GBS) in Latin America and the Caribbean before and during the 2015\u20132016 Zika virus epidemic: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2019;13: e0007622.","journal-title":"PLoS Negl Trop Dis"},{"key":"9316_CR9","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/oxfordjournals.aje.a115973","volume":"133","author":"TJ Safranek","year":"1991","unstructured":"Safranek TJ, Lawrence DN, Kuriand LT, Culver DH, Wiederholt WC, Hayner NS, et al. Reassessment of the association between Guillain-Barr\u00e9 syndrome and receipt of swine influenza vaccine in 1976\u20131977: results of a two-state study. Am J Epidemiol. 1991;133:940\u201351.","journal-title":"Am J Epidemiol"},{"key":"9316_CR10","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1001\/jama.292.20.2478","volume":"292","author":"P Haber","year":"2004","unstructured":"Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, et al. Guillain-Barr\u00e9 syndrome following Influenza vaccination. JAMA. 2004;292:2478\u201381.","journal-title":"JAMA"},{"key":"9316_CR11","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1001\/archinte.166.20.2217","volume":"166","author":"DN Juurlink","year":"2006","unstructured":"Juurlink DN, Stukel TA, Kwong J, Kopp A, McGeer A, Upshur RE, et al. Guillain-Barre syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006;166:2217\u201321.","journal-title":"Arch Intern Med"},{"key":"9316_CR12","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.1016\/j.vaccine.2011.08.069","volume":"29","author":"N Andrews","year":"2011","unstructured":"Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barre syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series. Vaccine. 2011;29:7878\u201382.","journal-title":"Vaccine"},{"key":"9316_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2012.7342","volume":"308","author":"P De Wals","year":"2012","unstructured":"De Wals P, Deceuninck G, Toth E, Boulianne N, Brunet D, Boucher RM, et al. Risk of Guillain-Barre syndrome following H1N1 influenza vaccination in Quebec. JAMA. 2012;308:175\u201381.","journal-title":"JAMA"},{"key":"9316_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d3908","volume":"343","author":"J Dieleman","year":"2011","unstructured":"Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ. 2011;343: d3908.","journal-title":"BMJ"},{"key":"9316_CR15","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/aje\/kws195","volume":"175","author":"SK Greene","year":"2012","unstructured":"Greene SK, Rett M, Weintraub ES, Li L, Yin R, Amato AA, et al. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009\u20132010. Am J Epidemiol. 2012;175:1100\u20139.","journal-title":"Am J Epidemiol"},{"key":"9316_CR16","doi-asserted-by":"crossref","unstructured":"Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological complications of COVID 19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021;13.","DOI":"10.7759\/cureus.13426"},{"issue":"9","key":"9316_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.rce.2021.05.005","volume":"221","author":"IF Aomar-Mill\u00e1n","year":"2021","unstructured":"Aomar-Mill\u00e1n IF, de Victoria-Carazo JM, Peregrina-Rivas JA, Villegas-Rodr\u00edguez I. COVID-19, Guillain-Barr\u00e9 y vacuna.\u00a0Una mezcla peligrosa. Rev Clin Esp. 2021;221(9):555.","journal-title":"Rev Clin Esp"},{"issue":"3","key":"9316_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/jnnp-2021-327027","volume":"93","author":"GB Bonifacio","year":"2022","unstructured":"Bonifacio GB, Patel D, Cook S, Purcaru E, Couzins M, Domjan J, et al. Bilateral facial weakness with paraesthesia variant of Guillain-Barr\u00e9 syndrome following Vaxzevria COVID-19 vaccine. J Neurol Neurosurg Psychiatry. 2022;93(3):341\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9316_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/ncn3.12537","volume":"9","author":"J James","year":"2021","unstructured":"James J, Jose J, Gafoor VA, Smita B, Balaram N. Guillain-Barr\u00e9 syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: a case series. Neurol Clin Neurosci. 2021;9:402\u20135.","journal-title":"Neurol Clin Neurosci"},{"key":"9316_CR20","doi-asserted-by":"crossref","unstructured":"Jain E, Pandav K, Regmi P, Michel G, Altshuler I. Facial diplegia: a rare, atypical variant of Guillain-Barr\u00e9 syndrome and Ad26. COV2. S Vaccine. Cureus. 2021;13.","DOI":"10.7759\/cureus.16612"},{"key":"9316_CR21","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27:2144\u201353.","journal-title":"Nat Med"},{"key":"9316_CR22","doi-asserted-by":"crossref","unstructured":"Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February-July 2021. Jama. 2021;326:1606\u201313.","DOI":"10.1001\/jama.2021.16496"},{"key":"9316_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.","journal-title":"BMJ"},{"key":"9316_CR24","doi-asserted-by":"crossref","unstructured":"Ghazanfar H, Qazi R, Ghazanfar A, Iftekhar S. Significance of Brighton criteria in the early diagnosis and management of Guillain-Barr\u00e9 syndrome. Cureus. 2020;12:e8318-e.","DOI":"10.7759\/cureus.8318"},{"key":"9316_CR25","doi-asserted-by":"publisher","first-page":"E1766","DOI":"10.1503\/cmaj.210947","volume":"193","author":"L Ling","year":"2021","unstructured":"Ling L, Bagshaw SM, Villeneuve P-M. Guillain-Barr\u00e9 syndrome after SARS-CoV-2 vaccination in a patient with previous vaccine-associated Guillain-Barr\u00e9 syndrome. CMAJ. 2021;193:E1766\u20139.","journal-title":"CMAJ"},{"key":"9316_CR26","doi-asserted-by":"crossref","unstructured":"Finsterer J. Exacerbating Guillain\u2013Barr\u00e9 syndrome eight days after vector-based COVID-19 vaccination. Case Reports in Infectious Diseases. 2021;2021.","DOI":"10.1155\/2021\/3619131"},{"key":"9316_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108818","volume":"230","author":"M Garc\u00eda-Grimshaw","year":"2021","unstructured":"Garc\u00eda-Grimshaw M, Michel-Ch\u00e1vez A, Vera-Zertuche JM, Galnares-Olalde JA, Hern\u00e1ndez-Vanegas LE, Figueroa-Cucurachi M, et al. Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine. Clin Immunol. 2021;230: 108818.","journal-title":"Clin Immunol"},{"key":"9316_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577719","volume":"360","author":"WM Oo","year":"2021","unstructured":"Oo WM, Giri P, De Souza A. AstraZeneca COVID-19 vaccine and Guillain-Barr\u00e9 syndrome in Tasmania: a causal link? J Neuroimmunol. 2021;360: 577719.","journal-title":"J Neuroimmunol"},{"key":"9316_CR29","doi-asserted-by":"crossref","unstructured":"Abi\u010di\u0107 A, Adamec I, Habek M. Miller Fisher syndrome following Pfizer COVID-19 vaccine. Neurological Sciences. 2021:1\u20133.","DOI":"10.1007\/s10072-021-05776-0"},{"key":"9316_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.26144","volume":"90","author":"CM Allen","year":"2021","unstructured":"Allen CM, Ramsamy S, Tarr AW, Tighe PJ, Irving WL, Tanasescu R, et al. Guillain-Barr\u00e9 syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021;90:315\u20138.","journal-title":"Ann Neurol"},{"key":"9316_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.12691\/ajmcr-9-8-10","volume":"9","author":"S Azam","year":"2021","unstructured":"Azam S, Khalil A, Taha A. Guillain-Barr\u00e9 syndrome in a 67-year-old male post COVID-19 vaccination (Astra Zeneca). American Journal of Medical Case Reports. 2021;9:424\u20137.","journal-title":"American Journal of Medical Case Reports"},{"key":"9316_CR32","doi-asserted-by":"crossref","unstructured":"Bax F, Gigli GL, Belgrado E, Brunelli L, Valente M. Guillain\u2013Barr\u00e9 syndrome following COVID-19 immunization: a report of two cases. Acta Neurologica Belgica. 2021:1\u20133.","DOI":"10.1007\/s13760-021-01798-9"},{"key":"9316_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/jnnp-2021-327027","volume":"93","author":"GB Bonifacio","year":"2022","unstructured":"Bonifacio GB, Patel D, Cook S, Purcaru E, Couzins M, Domjan J, et al. Bilateral facial weakness with paraesthesia variant of Guillain-Barr\u00e9 syndrome following Vaxzevria COVID-19 vaccine. J Neurol Neurosurg Psychiatry. 2022;93:341\u20132.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9316_CR34","doi-asserted-by":"crossref","unstructured":"Bouattour N, Hdiji O, Sakka S, Fakhfakh E, Moalla K, Daoud S, et al. Guillain-Barr\u00e9 syndrome following the first dose of Pfizer-BioNTech COVID-19 vaccine: case report and review of reported cases. Neurological Sciences. 2021:1\u20137.","DOI":"10.1007\/s10072-021-05733-x"},{"key":"9316_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-246701","volume":"14","author":"YL Dang","year":"2021","unstructured":"Dang YL, Bryson A. Miller-Fisher syndrome and Guillain-Barre syndrome overlap syndrome in a patient post Oxford-AstraZeneca SARS-CoV-2 vaccination. BMJ Case Reports CP. 2021;14: e246701.","journal-title":"BMJ Case Reports CP"},{"key":"9316_CR36","doi-asserted-by":"crossref","unstructured":"da Silva GF, da Silva CF, Oliveira RENdN, Romancini F, Mendes RM, Locks A, et al.\u00a0Guillain\u2013Barr\u00e9\u00a0syndrome after coronavirus disease 2019 vaccine: a temporal association.\u00a0Clin Exp Neuroimmunol. 2022;13(2):92\u20134.","DOI":"10.1111\/cen3.12678"},{"key":"9316_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-243629","volume":"14","author":"T Hasan","year":"2021","unstructured":"Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barr\u00e9 syndrome following COVID-19 vaccine. BMJ Case Reports CP. 2021;14: e243629.","journal-title":"BMJ Case Reports CP"},{"key":"9316_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/lt.26279","volume":"28","author":"DL Hughes","year":"2022","unstructured":"Hughes DL, Brunn JA, Jacobs J, Todd PK, Askari FK, Fontana RJ. Guillain-Barr\u00e9 syndrome after COVID-19 mRNA vaccination in a liver transplantation recipient with favorable treatment response. Liver Transpl. 2022;28:134\u20137.","journal-title":"Liver Transpl"},{"key":"9316_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106887","volume":"208","author":"A Introna","year":"2021","unstructured":"Introna A, Caputo F, Santoro C, Guerra T, Ucci M, Mezzapesa DM, et al. Guillain-Barr\u00e9 syndrome after AstraZeneca COVID-19-vaccination: a causal or casual association? Clin Neurol Neurosurg. 2021;208: 106887.","journal-title":"Clin Neurol Neurosurg"},{"key":"9316_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244527","volume":"14","author":"G Kanabar","year":"2021","unstructured":"Kanabar G, Wilkinson P. Guillain-Barr\u00e9 syndrome presenting with facial diplegia following COVID-19 vaccination in two patients. BMJ Case Reports CP. 2021;14: e244527.","journal-title":"BMJ Case Reports CP"},{"key":"9316_CR41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.32598\/bcn.2021.3565.1","volume":"12","author":"N Karimi","year":"2021","unstructured":"Karimi N, Boostani R, Fatehi F, Panahi A, Okhovat AA, Ziaadini B, et al. Guillain-Barre syndrome and COVID-19 vaccine: a report of nine patients. Basic and Clinical Neuroscience. 2021;12:703\u201310.","journal-title":"Basic and Clinical Neuroscience"},{"key":"9316_CR42","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1212\/WNL.0000000000011881","volume":"96","author":"AMM Loza","year":"2021","unstructured":"Loza AMM, Holroyd KB, Johnson SA, Pilgrim DM, Amato AA. Guillain-Barr\u00e9 syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality. Neurology. 2021;96:1052\u20134.","journal-title":"Neurology"},{"key":"9316_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pediatrneurol.2021.10.003","volume":"126","author":"E Malamud","year":"2022","unstructured":"Malamud E, Otallah SI, Caress JB, Lapid DJ. Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in an adolescent. Pediatr Neurol. 2022;126:9\u201310.","journal-title":"Pediatr Neurol"},{"key":"9316_CR44","doi-asserted-by":"crossref","unstructured":"Maramattom BV, Krishnan P, Paul R, Padmanabhan S, Cherukudal Vishnu Nampoothiri S, Syed AA, et al. Guillain\u2010Barr\u00e9 syndrome following ChAdOx1\u2010S\/nCoV\u201019 vaccine. Annals of neurology. 2021;90:312\u20134.","DOI":"10.1002\/ana.26143"},{"key":"9316_CR45","doi-asserted-by":"crossref","unstructured":"Masuccio FG, Comi C, Solaro C. Guillain\u2013Barr\u00e8 syndrome following COVID-19 vaccine mRNA-1273: a case report. Acta Neurologica Belgica. 2021:1\u20133.","DOI":"10.1007\/s13760-021-01838-4"},{"key":"9316_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4756","volume":"9","author":"AS Matarneh","year":"2021","unstructured":"Matarneh AS, Al-battah AH, Farooqui K, Ghamoodi M, Alhatou M. COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clinical Case Reports. 2021;9: e04756.","journal-title":"Clinical Case Reports"},{"key":"9316_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-244125","volume":"14","author":"N McKean","year":"2021","unstructured":"McKean N, Chircop C. Guillain-Barr\u00e9 syndrome after COVID-19 vaccination. BMJ Case Reports CP. 2021;14: e244125.","journal-title":"BMJ Case Reports CP"},{"key":"9316_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/CND.0000000000000376","volume":"23","author":"NM Michaelson","year":"2021","unstructured":"Michaelson NM, Lam T, Malhotra A, Schiff ND, MacGowan DJL. Miller Fisher syndrome presenting after a second dose of Pfizer-BioNTech vaccination in a patient with resolved COVID-19: a case report. J Clin Neuromuscul Dis. 2021;23:113\u20135.","journal-title":"J Clin Neuromuscul Dis"},{"key":"9316_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577691","volume":"359","author":"YG Min","year":"2021","unstructured":"Min YG, Ju W, Ha Y-E, Ban J-J, Lee SA, Sung J-J, et al. Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: report of two cases and review of literature. J Neuroimmunol. 2021;359: 577691.","journal-title":"J Neuroimmunol"},{"key":"9316_CR50","doi-asserted-by":"crossref","unstructured":"Morehouse ZP, Paulus A, Jasti SA, Bing X. A rare variant of Guillain-Barre syndrome following Ad26. COV2. S vaccination. Cureus. 2021;13.","DOI":"10.7759\/cureus.18153"},{"key":"9316_CR51","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1007\/s10072-021-05467-w","volume":"42","author":"NA Nasuelli","year":"2021","unstructured":"Nasuelli NA, De Marchi F, Cecchin M, De Paoli I, Onorato S, Pettinaroli R, et al. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine. Neurol Sci. 2021;42:4747\u20139.","journal-title":"Neurol Sci"},{"key":"9316_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-021-02489-x","volume":"21","author":"Y Nishiguchi","year":"2021","unstructured":"Nishiguchi Y, Matsuyama H, Maeda K, Shindo A, Tomimoto H. Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination. BMC Neurol. 2021;21:1\u20136.","journal-title":"BMC Neurol"},{"key":"9316_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2021.e01143","volume":"24","author":"O Ogbebor","year":"2021","unstructured":"Ogbebor O, Seth H, Min Z, Bhanot N. Guillain-Barr\u00e9 syndrome following the first dose of SARS-CoV-2 vaccine: a temporal occurrence, not a causal association. IDCases. 2021;24: e01143.","journal-title":"IDCases"},{"key":"9316_CR54","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ana.26218","volume":"90","author":"J Osowicki","year":"2021","unstructured":"Osowicki J, Morgan H, Harris A, Crawford NW, Buttery JP, Kiers L. Guillain-Barr\u00e9 syndrome in an Australian state using both mRNA and adenovirus-vector SARS-CoV-2 vaccines. Ann Neurol. 2021;90:856\u20138.","journal-title":"Ann Neurol"},{"key":"9316_CR55","doi-asserted-by":"crossref","unstructured":"Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep. 2021;14.","DOI":"10.1136\/bcr-2021-242956"},{"key":"9316_CR56","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/neurolint13030040","volume":"13","author":"A Prasad","year":"2021","unstructured":"Prasad A, Hurlburt G, Podury S, Tandon M, Kingree S, Sriwastava S. A novel case of bifacial diplegia variant of Guillain-Barr\u00e9 syndrome following Janssen COVID-19 vaccination. Neurol Int. 2021;13:404\u20139.","journal-title":"Neurol Int"},{"key":"9316_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102540","volume":"67","author":"A Razok","year":"2021","unstructured":"Razok A, Shams A, Almeer A, Zahid M. Post-COVID-19 vaccine Guillain-Barr\u00e9 syndrome; first reported case from Qatar. Ann Med Surg (Lond). 2021;67: 102540.","journal-title":"Ann Med Surg (Lond)"},{"key":"9316_CR58","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jemermed.2021.07.062","volume":"61","author":"A Rossetti","year":"2021","unstructured":"Rossetti A, Gheihman G, O\u2019Hare M, Kosowsky JM. Guillain-Barr\u00e9 syndrome presenting as facial diplegia after COVID-19 vaccination: a case report. J Emerg Med. 2021;61:e141\u20135.","journal-title":"J Emerg Med"},{"key":"9316_CR59","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1080\/21645515.2021.1954826","volume":"17","author":"R Scendoni","year":"2021","unstructured":"Scendoni R, Petrelli C, Scaloni G, Logullo FO. Electromyoneurography and laboratory findings in a case of Guillain-Barr\u00e9 syndrome after second dose of Pfizer COVID-19 vaccine. Hum Vaccin Immunother. 2021;17:4093\u20136.","journal-title":"Hum Vaccin Immunother"},{"key":"9316_CR60","doi-asserted-by":"publisher","first-page":"4401","DOI":"10.1007\/s10072-021-05523-5","volume":"42","author":"M Trimboli","year":"2021","unstructured":"Trimboli M, Zoleo P, Arabia G, Gambardella A. Guillain-Barr\u00e9 syndrome following BNT162b2 COVID-19 vaccine. Neurol Sci. 2021;42:4401\u20132.","journal-title":"Neurol Sci"},{"key":"9316_CR61","doi-asserted-by":"publisher","first-page":"286","DOI":"10.18071\/isz.74.0286","volume":"74","author":"NK Tutar","year":"2021","unstructured":"Tutar NK, Eyig\u00fcrb\u00fcz T, Yildirim Z, Kale N. A variant of Guillain-Barre syndrome after SARS-CoV-2 vaccination: AMSAN. Ideggyogyaszati Szemle. 2021;74:286\u20138.","journal-title":"Ideggyogyaszati Szemle"},{"key":"9316_CR62","doi-asserted-by":"crossref","unstructured":"Tabatabaee S, Rezania F, Alwedaie SMJ, Malekdar E, Badi Z, Tabatabaei SM, et al. Post COVID-19 vaccination Guillain-Barre syndrome: three cases. Human Vaccines & Immunotherapeutics. 2022:1\u20135.","DOI":"10.1080\/21645515.2022.2045153"},{"key":"9316_CR63","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"SE Leonhard","year":"2019","unstructured":"Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat Rev Neurol. 2019;15:671\u201383.","journal-title":"Nat Rev Neurol"},{"key":"9316_CR64","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N Engl J Med. 2021;385:2348\u201360.","journal-title":"N Engl J Med"},{"key":"9316_CR65","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603\u201315.","journal-title":"N Engl J Med"},{"key":"9316_CR66","doi-asserted-by":"crossref","unstructured":"Perez-Lloret S, Petrovsky N, Alami A, Crispo J, Mattison D, Otero-Losadsa M, et al. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom. medRxiv. 2021.","DOI":"10.1101\/2021.09.28.21264245"},{"key":"9316_CR67","doi-asserted-by":"crossref","unstructured":"Hanson KE, Goddard K, Lewis N, Fireman B, Myers TR, Bakshi N, et al. Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the vaccine safety datalink. medRxiv. 2021.","DOI":"10.1101\/2021.12.03.21266419"},{"key":"9316_CR68","doi-asserted-by":"crossref","unstructured":"Maroufi SF, Naderi Behdani F, Rezania F, Tanhapour Khotbehsara S, Mirzaasgari Z. Longitudinally extensive transverse myelitis after COVID-19 vaccination: case report and review of literature. Human Vaccines & Immunotherapeutics. 2022:1\u20134.","DOI":"10.1080\/21645515.2022.2040239"},{"key":"9316_CR69","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","volume":"8","author":"M Vadal\u00e0","year":"2017","unstructured":"Vadal\u00e0 M, Poddighe D, Laurino C, Palmieri B. Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? Epma j. 2017;8:295\u2013311.","journal-title":"Epma j"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-022-09316-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-022-09316-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T13:18:00Z","timestamp":1668604680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-022-09316-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":69,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9316"],"URL":"https:\/\/doi.org\/10.1007\/s12026-022-09316-6","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"10 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}